Masitinib AB Science (masitinib)
Orphan
- Region
- 🇪🇺 EU
- Active substance
- masitinib
- Company
- AB Science
- Status
- Refused
- Therapeutic area
- Amyotrophic Lateral Sclerosis
- CHMP opinion
- Thu 27 Jun 2024
- Designations
- Orphan
- Application
- EMEA/H/C/005897
- ATC
- L01EX06
- Official record
- www.ema.europa.eu
Indication
In combination with riluzole for the treatment of adult patients with amyotrophic lateral sclerosis (ALS)
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Masipro Refused · AB Science
- 🇪🇺 Alsitek Refused · AB Science
- 🇪🇺 Masiviera Refused · AB Science
- 🇪🇺 Masican Refused · AB Science
Follow Masitinib AB Science
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.